However, targeted therapy, e.g., cetuximab, an epidermal growth factor receptor inhibitor, has demonstrated survival benefit in HNSCC patients with locoregional failure or distant metastasis. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.